Next Article in Journal
Micro-RNAs in Response to Active Forms of Vitamin D3 in Human Leukemia and Lymphoma Cells
Next Article in Special Issue
The Expression of Connexin 37, 40, 43, 45 and Pannexin 1 in the Early Human Retina and Choroid Development and Tumorigenesis
Previous Article in Journal
An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of the MSTN Gene Inhibits Pre-mRNA Maturation to Act as a Novel Myostatin Inhibitor
Previous Article in Special Issue
Connexin Expression Is Altered in Liver Development of Yotari (dab1 -/-) Mice
 
 
Article

Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels

1
Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
2
Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
*
Author to whom correspondence should be addressed.
These authors equally contributed to this work.
Academic Editor: Jose L. Mauriz
Int. J. Mol. Sci. 2022, 23(9), 5018; https://doi.org/10.3390/ijms23095018
Received: 19 April 2022 / Revised: 26 April 2022 / Accepted: 26 April 2022 / Published: 30 April 2022
(This article belongs to the Special Issue Connexin and Pannexin Signaling in Health and Disease 2.0)
Connexin43 (Cx43) hemichannels form a pathway for cellular communication between the cell and its extracellular environment. Under pathological conditions, Cx43 hemichannels release adenosine triphosphate (ATP), which triggers inflammation. Over the past two years, azithromycin, chloroquine, dexamethasone, favipiravir, hydroxychloroquine, lopinavir, remdesivir, ribavirin, and ritonavir have been proposed as drugs for the treatment of the coronavirus disease 2019 (COVID-19), which is associated with prominent systemic inflammation. The current study aimed to investigate if Cx43 hemichannels, being key players in inflammation, could be affected by these drugs which were formerly designated as COVID-19 drugs. For this purpose, Cx43-transduced cells were exposed to these drugs. The effects on Cx43 hemichannel activity were assessed by measuring extracellular ATP release, while the effects at the transcriptional and translational levels were monitored by means of real-time quantitative reverse transcriptase polymerase chain reaction analysis and immunoblot analysis, respectively. Exposure to lopinavir and ritonavir combined (4:1 ratio), as well as to remdesivir, reduced Cx43 mRNA levels. None of the tested drugs affected Cx43 protein expression. View Full-Text
Keywords: COVID-19; drug; connexin43; hemichannel; cellular communication COVID-19; drug; connexin43; hemichannel; cellular communication
Show Figures

Figure 1

MDPI and ACS Style

Cooreman, A.; Caufriez, A.; Tabernilla, A.; Van Campenhout, R.; Leroy, K.; Kadam, P.; Sanz Serrano, J.; dos Santos Rodrigues, B.; Annaert, P.; Vinken, M. Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. Int. J. Mol. Sci. 2022, 23, 5018. https://doi.org/10.3390/ijms23095018

AMA Style

Cooreman A, Caufriez A, Tabernilla A, Van Campenhout R, Leroy K, Kadam P, Sanz Serrano J, dos Santos Rodrigues B, Annaert P, Vinken M. Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. International Journal of Molecular Sciences. 2022; 23(9):5018. https://doi.org/10.3390/ijms23095018

Chicago/Turabian Style

Cooreman, Axelle, Anne Caufriez, Andrés Tabernilla, Raf Van Campenhout, Kaat Leroy, Prashant Kadam, Julen Sanz Serrano, Bruna dos Santos Rodrigues, Pieter Annaert, and Mathieu Vinken. 2022. "Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels" International Journal of Molecular Sciences 23, no. 9: 5018. https://doi.org/10.3390/ijms23095018

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop